134 related articles for article (PubMed ID: 32019854)
1. Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes.
Maffi P; Lundgren T; Tufveson G; Rafael E; Shaw JAM; Liew A; Saudek F; Witkowski P; Golab K; Bertuzzi F; Gustafsson B; Daffonchio L; Ruffini PA; Piemonti L;
Diabetes Care; 2020 Apr; 43(4):710-718. PubMed ID: 32019854
[TBL] [Abstract][Full Text] [Related]
2. Targeting CXCR1/2 in the first multicenter, double-blinded, randomized trial in autologous islet transplant recipients.
Witkowski P; Wijkstrom M; Bachul PJ; Morgan KA; Levy M; Onaca N; Chaidarun SS; Gardner T; Shapiro AMJ; Posselt A; Ahmad SA; Daffonchio L; Ruffini PA; Bellin MD
Am J Transplant; 2021 Nov; 21(11):3714-3724. PubMed ID: 34033222
[TBL] [Abstract][Full Text] [Related]
3. Post-Hoc Analysis of a Randomized, Double Blind, Prospective Study at the University of Chicago: Additional Standardizations of Trial Protocol are Needed to Evaluate the Effect of a CXCR1/2 Inhibitor in Islet Allotransplantation.
Bachul PJ; Golab K; Basto L; Zangan S; Pyda JS; Perez-Gutierrez A; Borek P; Wang LJ; Tibudan M; Tran DK; Anteby R; Generette GS; Chrzanowski J; Fendler W; Perea L; Jayant K; Lucander A; Thomas C; Philipson L; Millis JM; Fung J; Witkowski P
Cell Transplant; 2021; 30():9636897211001774. PubMed ID: 33908301
[TBL] [Abstract][Full Text] [Related]
4. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.
Citro A; Cantarelli E; Maffi P; Nano R; Melzi R; Mercalli A; Dugnani E; Sordi V; Magistretti P; Daffonchio L; Ruffini PA; Allegretti M; Secchi A; Bonifacio E; Piemonti L
J Clin Invest; 2012 Oct; 122(10):3647-51. PubMed ID: 22996693
[TBL] [Abstract][Full Text] [Related]
5. A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery.
Opfermann P; Derhaschnig U; Felli A; Wenisch J; Santer D; Zuckermann A; Dworschak M; Jilma B; Steinlechner B
Clin Exp Immunol; 2015 Apr; 180(1):131-42. PubMed ID: 25402332
[TBL] [Abstract][Full Text] [Related]
6. Anti-Inflammatory Strategies in Intrahepatic Islet Transplantation: A Comparative Study in Preclinical Models.
Citro A; Cantarelli E; Pellegrini S; Dugnani E; Piemonti L
Transplantation; 2018 Feb; 102(2):240-248. PubMed ID: 28902069
[TBL] [Abstract][Full Text] [Related]
7. CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice.
Citro A; Valle A; Cantarelli E; Mercalli A; Pellegrini S; Liberati D; Daffonchio L; Kastsiuchenka O; Ruffini PA; Battaglia M; Allegretti M; Piemonti L
Diabetes; 2015 Apr; 64(4):1329-40. PubMed ID: 25315007
[TBL] [Abstract][Full Text] [Related]
8. Reparixin, a specific interleukin-8 inhibitor, has no effects on inflammation during endotoxemia.
Leitner JM; Mayr FB; Firbas C; Spiel AO; Steinlechner B; Novellini R; Jilma B
Int J Immunopathol Pharmacol; 2007; 20(1):25-36. PubMed ID: 17346425
[TBL] [Abstract][Full Text] [Related]
9. Reparixin, a CXCR1/2 inhibitor in islet allotransplantation.
Pawlick RL; Wink J; Pepper AR; Bruni A; Abualhassen N; Rafiei Y; Gala-Lopez B; Bral M; Shapiro AM
Islets; 2016 Sep; 8(5):115-24. PubMed ID: 27328412
[TBL] [Abstract][Full Text] [Related]
10. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Goldstein LJ; Perez RP; Yardley D; Han LK; Reuben JM; Gao H; McCanna S; Butler B; Ruffini PA; Liu Y; Rosato RR; Chang JC
Breast Cancer Res; 2020 Jan; 22(1):4. PubMed ID: 31924241
[TBL] [Abstract][Full Text] [Related]
11. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats.
Kim HY; Choi JH; Kang YJ; Park SY; Choi HC; Kim HS
Biol Pharm Bull; 2011; 34(1):120-7. PubMed ID: 21212529
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol.
Ryan EA; Lakey JR; Rajotte RV; Korbutt GS; Kin T; Imes S; Rabinovitch A; Elliott JF; Bigam D; Kneteman NM; Warnock GL; Larsen I; Shapiro AM
Diabetes; 2001 Apr; 50(4):710-9. PubMed ID: 11289033
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of CXCR1 and CXCR2 chemokine receptors attenuates acute inflammation, preserves gray matter and diminishes autonomic dysreflexia after spinal cord injury.
Marsh DR; Flemming JM
Spinal Cord; 2011 Mar; 49(3):337-44. PubMed ID: 20877331
[TBL] [Abstract][Full Text] [Related]
14. Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.
Piemonti L; Keymeulen B; Gillard P; Linn T; Bosi E; Rose L; Pozzilli P; Giorgino F; Cossu E; Daffonchio L; Goisis G; Ruffini PA; Maurizi AR; Mantelli F; Allegretti M
Diabetes Obes Metab; 2022 Sep; 24(9):1840-1849. PubMed ID: 35589610
[TBL] [Abstract][Full Text] [Related]
15. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes.
Hering BJ; Kandaswamy R; Ansite JD; Eckman PM; Nakano M; Sawada T; Matsumoto I; Ihm SH; Zhang HJ; Parkey J; Hunter DW; Sutherland DE
JAMA; 2005 Feb; 293(7):830-5. PubMed ID: 15713772
[TBL] [Abstract][Full Text] [Related]
16. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus.
Warnock GL; Meloche RM; Thompson D; Shapiro RJ; Fung M; Ao Z; Ho S; He Z; Dai LJ; Young L; Blackburn L; Kozak S; Kim PT; Al-Adra D; Johnson JD; Liao YH; Elliott T; Verchere CB
Arch Surg; 2005 Aug; 140(8):735-44. PubMed ID: 16103282
[TBL] [Abstract][Full Text] [Related]
17. Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice.
Sousa LF; Coelho FM; Rodrigues DH; Campos AC; Barcelos Lda S; Teixeira MM; Rachid MA; Teixeira AL
Clinics (Sao Paulo); 2013; 68(3):391-4. PubMed ID: 23644861
[TBL] [Abstract][Full Text] [Related]
18. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center.
Goss JA; Schock AP; Brunicardi FC; Goodpastor SE; Garber AJ; Soltes G; Barth M; Froud T; Alejandro R; Ricordi C
Transplantation; 2002 Dec; 74(12):1761-6. PubMed ID: 12499894
[TBL] [Abstract][Full Text] [Related]
19. International trial of the Edmonton protocol for islet transplantation.
Shapiro AM; Ricordi C; Hering BJ; Auchincloss H; Lindblad R; Robertson RP; Secchi A; Brendel MD; Berney T; Brennan DC; Cagliero E; Alejandro R; Ryan EA; DiMercurio B; Morel P; Polonsky KS; Reems JA; Bretzel RG; Bertuzzi F; Froud T; Kandaswamy R; Sutherland DE; Eisenbarth G; Segal M; Preiksaitis J; Korbutt GS; Barton FB; Viviano L; Seyfert-Margolis V; Bluestone J; Lakey JR
N Engl J Med; 2006 Sep; 355(13):1318-30. PubMed ID: 17005949
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells.
Fu S; Chen X; Lin HJ; Lin J
Int J Oncol; 2018 Jul; 53(1):349-357. PubMed ID: 29749433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
